Undisclosed PARG inhibitor
/ Satya Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 08, 2024
Covalent PARG inhibitors show sustained target engagement and superior anticancer activity
(EORTC-NCI-AACR 2024)
- "Lead identification is completed with covalent PARG inhibitors. Currently, Lead optimisation is ongoing to improve physicochemical properties and PK properties."
Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • PARP1
1 to 1
Of
1
Go to page
1